Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy

SIMPLE SUMMARY: Since the recent approval of osimertinib, a third generation tyrosine kinase inhibitor (TKI) targeting EGFR in non-small cell lung cancer (NSCLC), tracing the resistance mechanisms that yield to failure of osimertinib has become of interest. As the spectrum of osimertinib-resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Jóri, Balázs, Schatz, Stefanie, Kaller, Len, Kah, Bettina, Roeper, Julia, Ramdani, Hayat O., Diehl, Linda, Hoffknecht, Petra, Grohé, Christian, Griesinger, Frank, Tiemann, Markus, Heukamp, Lukas C., Falk, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227553/
https://www.ncbi.nlm.nih.gov/pubmed/34201252
http://dx.doi.org/10.3390/cancers13122861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227553/
https://www.ncbi.nlm.nih.gov/pubmed/34201252
http://dx.doi.org/10.3390/cancers13122861

Ejemplares similares